BACKGROUND/AIMS: It has been shown that blockade of TGF-beta1 signaling with Smad7 prevents experimental peritoneal fibrosis. The present study investigated whether Smad7 has a therapeutic effect on established peritoneal fibrosis associated with peritoneal dialysis (PD). METHODS: A rat model of peritoneal fibrosis was induced by a daily intraperitoneal infusion of 4.25% Dianeal. After peritoneal fibrosis had been established on day 14, groups of 6 rats were treated intraperitoneally with gene transfer of Smad7 or control plasmids using an ultrasound-microbubble-mediated system for 2 weeks until day 28. In addition, a group of 6 diseased rats was euthanized on day 14 before treatment as the basal disease control. RESULTS: Compared to the control-treatment animals on day 28, real-time PCR, Western blot, and confocal microscopy revealed that Smad7 gene transfer significantly attenuated the increased peritoneal fibrosis including the thickening of fibrotic peritoneum, accumulation of alpha-SMA and collagen I, and an improvement in peritoneal dysfunction (all p < 0.05). Importantly, Smad7 treatment also improved the severity of peritoneal fibrosis and functional impairment when compared to those on day 14 before treatment (all p < 0.05). Inhibition of the established peritoneal fibrosis by Smad7 was associated with an abrogation of TGF-beta signaling and upregulation of TGF-beta1 and PAI-1. CONCLUSIONS: Smad7 gene therapy is able to inhibit established peritoneal fibrosis in a rat model of PD. Results from this study suggest that Smad7 may be a therapeutic agent for the treatment of peritoneal fibrosis associated with PD.
BACKGROUND/AIMS: It has been shown that blockade of TGF-beta1 signaling with Smad7 prevents experimental peritoneal fibrosis. The present study investigated whether Smad7 has a therapeutic effect on established peritoneal fibrosis associated with peritoneal dialysis (PD). METHODS: A rat model of peritoneal fibrosis was induced by a daily intraperitoneal infusion of 4.25% Dianeal. After peritoneal fibrosis had been established on day 14, groups of 6 rats were treated intraperitoneally with gene transfer of Smad7 or control plasmids using an ultrasound-microbubble-mediated system for 2 weeks until day 28. In addition, a group of 6 diseased rats was euthanized on day 14 before treatment as the basal disease control. RESULTS: Compared to the control-treatment animals on day 28, real-time PCR, Western blot, and confocal microscopy revealed that Smad7 gene transfer significantly attenuated the increased peritoneal fibrosis including the thickening of fibrotic peritoneum, accumulation of alpha-SMA and collagen I, and an improvement in peritoneal dysfunction (all p < 0.05). Importantly, Smad7 treatment also improved the severity of peritoneal fibrosis and functional impairment when compared to those on day 14 before treatment (all p < 0.05). Inhibition of the established peritoneal fibrosis by Smad7 was associated with an abrogation of TGF-beta signaling and upregulation of TGF-beta1 and PAI-1. CONCLUSIONS:Smad7 gene therapy is able to inhibit established peritoneal fibrosis in a rat model of PD. Results from this study suggest that Smad7 may be a therapeutic agent for the treatment of peritoneal fibrosis associated with PD.
Authors: Ruihua Chen; Cancan Huang; Thomas A Morinelli; Maria Trojanowska; Richard V Paul Journal: J Am Soc Nephrol Date: 2002-04 Impact factor: 10.121
Authors: Peter J Margetts; Martin Kolb; Tom Galt; Catherine M Hoff; Ty R Shockley; Jack Gauldie Journal: J Am Soc Nephrol Date: 2001-10 Impact factor: 10.121
Authors: Hui Y Lan; Wei Mu; Naruya Tomita; Xiao R Huang; Jin H Li; Hong-Jian Zhu; Ryuichi Morishita; Richard J Johnson Journal: J Am Soc Nephrol Date: 2003-06 Impact factor: 10.121
Authors: Jesús Loureiro; Abelardo Aguilera; Rafael Selgas; Pilar Sandoval; Patricia Albar-Vizcaíno; María Luisa Pérez-Lozano; Vicente Ruiz-Carpio; Pedro L Majano; Santiago Lamas; Fernando Rodríguez-Pascual; Francisco Borras-Cuesta; Javier Dotor; Manuel López-Cabrera Journal: J Am Soc Nephrol Date: 2011-07-08 Impact factor: 10.121
Authors: Valentina Masola; Mario Bonomini; Silvio Borrelli; Lorenzo Di Liberato; Luigi Vecchi; Maurizio Onisto; Giovanni Gambaro; Roberto Palumbo; Arduino Arduini Journal: Int J Mol Sci Date: 2022-04-27 Impact factor: 6.208
Authors: Arthur C K Chung; Haiyan Zhang; Yao-Zhong Kong; Jia-Ju Tan; Xiao R Huang; Jeffrey B Kopp; Hui Y Lan Journal: J Am Soc Nephrol Date: 2009-12-03 Impact factor: 10.121